Most Read Articles
01 Nov 2013

Joint stiffness is defined as discomfort after a period of inactivity. It is associated with reduced or loss of range of motion in a joint.

01 Aug 2016
Etoricoxib exhibits a central mode of action and enhances pain and function in patients with painful knew osteoarthritis (OA), as presented in a randomised, double-blind, placebo-controlled, two-way crossover, four-week treatment study.
Stephen Padilla, 25 Nov 2016
The addition of supervised physiotherapy to usual care does not provide clinically important improvement in the management of simple ankle sprains in a general population of patients seeking hospital-based acute care, according to results of a recent randomized controlled trial.
24 Jul 2017
The toxic side-effects of chemotherapy appear to be induced by cell-free chromatin (cfCh) fragments released from dying cells, triggering DNA damage, apoptosis and inflammation in healthy cells, thereby exaggerating or amplifying the toxic effects caused by the drugs themselves, according to a study.

Adalimumab plus MTX effective in JIA-associated uveitis

20 May 2017

Combination therapy with methotrexate (MTX) and adalimumab, a human anti–tumour necrosis factor α monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, according to a recent report.


In the multicentre, double-blind study, researchers assessed the efficacy and safety of adalimumab in children and adolescents ≥2 years of age who had active JIA-associated uveitis and who were receiving a stable dose of MTX. The children were randomized in a 2:1 ratio to receive subcutaneous adalimumab (20 or 40 mg based on body weight) or placebo every 2 weeks until treatment failure or until 18 months had elapsed. They were followed-up for 2 years from the time of randomization. The primary endpoint was time to treatment failure.


The trial was halted early when the prespecified stopping criteria were met after the enrolment of 90 of 114 patients. It was clear that the therapy was effective as the treatment failure rate was 27 percent among adalimumab recipients but 60 percent among those in the placebo group (hazard ratio (HR), 0.25, 95 percent confidence interval (CI) 0.12–0.49; p<0.0001 (this HR was the prespecified stopping boundary). However, the rates of adverse events (10.07 events/patient-year vs 6.51 events/patient-year) and serious adverse events (0.29 events/patient-year vs 0.19 events/patient-year) were also higher among adalimumab recipients. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Nov 2013

Joint stiffness is defined as discomfort after a period of inactivity. It is associated with reduced or loss of range of motion in a joint.

01 Aug 2016
Etoricoxib exhibits a central mode of action and enhances pain and function in patients with painful knew osteoarthritis (OA), as presented in a randomised, double-blind, placebo-controlled, two-way crossover, four-week treatment study.
Stephen Padilla, 25 Nov 2016
The addition of supervised physiotherapy to usual care does not provide clinically important improvement in the management of simple ankle sprains in a general population of patients seeking hospital-based acute care, according to results of a recent randomized controlled trial.
24 Jul 2017
The toxic side-effects of chemotherapy appear to be induced by cell-free chromatin (cfCh) fragments released from dying cells, triggering DNA damage, apoptosis and inflammation in healthy cells, thereby exaggerating or amplifying the toxic effects caused by the drugs themselves, according to a study.